Moriyama K - Search Results

1

V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa.

Allmond LR, Ajayi T, Moriyama K, Wiener-Kronish JP, Sawa T. Allmond LR, et al. Among authors: moriyama k. J Clin Microbiol. 2004 Aug;42(8):3857-60. doi: 10.1128/JCM.42.8.3857-3860.2004. J Clin Microbiol. 2004. PMID: 15297549 Free PMC article.

2

The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.

Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barbançon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, Sawa T. Sato H, et al. Among authors: moriyama k. EMBO J. 2003 Jun 16;22(12):2959-69. doi: 10.1093/emboj/cdg290. EMBO J. 2003. PMID: 12805211 Free PMC article.

3

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model.

Faure K, Fujimoto J, Shimabukuro DW, Ajayi T, Shime N, Moriyama K, Spack EG, Wiener-Kronish JP, Sawa T. Faure K, et al. Among authors: moriyama k. J Immune Based Ther Vaccines. 2003 Aug 13;1(1):2. doi: 10.1186/1476-8518-1-2. J Immune Based Ther Vaccines. 2003. PMID: 12943554 Free PMC article.

4

Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.

Tamura M, Ajayi T, Allmond LR, Moriyama K, Wiener-Kronish JP, Sawa T. Tamura M, et al. Among authors: moriyama k. Biochem Biophys Res Commun. 2004 Apr 2;316(2):323-31. doi: 10.1016/j.bbrc.2004.02.050. Biochem Biophys Res Commun. 2004. PMID: 15020221

5

TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins.

Faure K, Sawa T, Ajayi T, Fujimoto J, Moriyama K, Shime N, Wiener-Kronish JP. Faure K, et al. Among authors: moriyama k. Respir Res. 2004 Feb 12;5(1):1. doi: 10.1186/1465-9921-5-1. Respir Res. 2004. PMID: 15040820 Free PMC article.

6

Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.

Pankhaniya RR, Tamura M, Allmond LR, Moriyama K, Ajayi T, Wiener-Kronish JP, Sawa T. Pankhaniya RR, et al. Among authors: moriyama k. Crit Care Med. 2004 Nov;32(11):2293-9. doi: 10.1097/01.ccm.0000145588.79063.07. Crit Care Med. 2004. PMID: 15640644

7

Proteomic analysis of undiluted lung epithelial lining fluid.

Kipnis E, Hansen K, Sawa T, Moriyama K, Zurawel A, Ishizaka A, Wiener-Kronish J. Kipnis E, et al. Among authors: moriyama k. Chest. 2008 Aug;134(2):338-345. doi: 10.1378/chest.07-1643. Chest. 2008. PMID: 18682457

8

Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.

Moriyama K, Wiener-Kronish JP, Sawa T. Moriyama K, et al. Microbiol Immunol. 2009 Nov;53(11):587-94. doi: 10.1111/j.1348-0421.2009.00165.x. Microbiol Immunol. 2009. PMID: 19903258 Free article.

9

Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.

Sawa T, Shimizu M, Moriyama K, Wiener-Kronish JP. Sawa T, et al. Among authors: moriyama k. Crit Care. 2014 Dec 13;18(6):668. doi: 10.1186/s13054-014-0668-9. Crit Care. 2014. PMID: 25672496 Free PMC article. Review.

10

The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T. Kinoshita M, et al. Among authors: moriyama k. Hum Vaccin Immunother. 2016 Nov;12(11):2833-2846. doi: 10.1080/21645515.2016.1209280. Epub 2016 Jul 25. Hum Vaccin Immunother. 2016. PMID: 27454613 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

834 results

Search Page

Filters